News Image

Why the quality investor may take a look at MERCK & CO. INC. (NYSE:MRK).

By Mill Chart

Last update: Jan 30, 2024

In this article we will dive into MERCK & CO. INC. (NYSE:MRK) as a possible candidate for quality investing. Investors should always do their own research, but we noticed MERCK & CO. INC. showing up in our Caviar Cruise quality screen, which makes it worth to investigate a bit more.

Looking into the quality metrics of MERCK & CO. INC.

  • MERCK & CO. INC. has demonstrated significant revenue growth over the past 5 years, with a 8.12% increase. This underscores the company's ability to adapt to market dynamics and capitalize on growth opportunities.
  • MERCK & CO. INC. demonstrates impressive performance in terms of ROIC excluding cash and goodwill, with a 23.7% ratio. This highlights the company's efficient utilization of capital and its focus on maximizing returns for investors.
  • MERCK & CO. INC. demonstrates a well-balanced Debt/Free Cash Flow Ratio of 2.65, indicating effective debt management and strong cash flow generation. This ratio suggests the company has a sustainable financial position and the capacity to allocate capital efficiently.
  • With a robust Profit Quality (5-year) ratio of 98.51%, MERCK & CO. INC. highlights its ability to consistently generate high-quality profits. This metric reflects the company's effective management and operational excellence in delivering reliable earnings over the long term.
  • The 5-year EBIT growth of MERCK & CO. INC. has been remarkable, with 15.32% increase. This demonstrates the company's ability to improve its operational efficiency and indicates its competitiveness within the market.
  • With EBIT 5-year growth outpacing its Revenue 5-year growth, MERCK & CO. INC. showcases its effective cost management and enhanced operational performance. This suggests the company's ability to generate higher earnings from its revenue streams.

A complete fundamental analysis of NYSE:MRK

ChartMill assigns a Fundamental Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple fundamental indicators and properties.

We assign a fundamental rating of 6 out of 10 to MRK. MRK was compared to 205 industry peers in the Pharmaceuticals industry. While MRK has a great profitability rating, there are some minor concerns on its financial health. MRK is not valued too expensively and it also shows a decent growth rate.

Our latest full fundamental report of MRK contains the most current fundamental analsysis.

More quality stocks can be found in our Caviar Cruise screen.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

MERCK & CO. INC.

NYSE:MRK (4/19/2024, 7:04:59 PM)

After market: 125.4 -0.38 (-0.3%)

125.78

+0.55 (+0.44%)

MRK News

News Imagea day ago - Merck Canada Inc.Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and

/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...

News Image3 days ago - InvestorPlaceComing FDA Approvals Could Send These 3 Drug Stocks Soaring

When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.

News Image4 days ago - InvestorPlace3 Dow Stocks to Buy Now: Q2 Edition

Although the idea of Dow stocks to buy now is patently boring, that could be a positive attribute amid the current backdrop.

News Image5 days ago - The Motley FoolBetter Growth Play: Merck or The Vanguard Growth Index Fund?

Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?

News Image7 days ago - The Motley FoolMerck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.

Being able to stop a drug's unwanted effects could lead to a larger market share.

News Image8 days ago - The Motley Fool1 New Green Flag for Moderna and Merck Stock

There's a new reason to believe that their joint projects are going well.

News Image8 days ago - InvestorPlace7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.

News Image9 days ago - Market News VideoSee Which Of The Latest 13F Filers Holds Merck & Co
News Image9 days ago - InvestorPlaceThe $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

News Image10 days ago - ChartmillWhen you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

MERCK & CO. INC. (NYSE:MRK): good value for what you're paying.

News Image10 days ago - Market News VideoMRK December 2026 Options Begin Trading
News Image12 days ago - Market News VideoMonday Sector Laggards: Energy, Healthcare
MRK Links
Follow us for more